Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved an expanded indication for Merck & Co's anti-nausea drug Emend for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.
Subscribe to our email newsletter
The drug is already approved for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy treatments. Both approvals are for Emend in combination with other anti-emetics.
The latest FDA approval for Emend is based on the findings of a study that enrolled 866 breast cancer patients, of whom 99.5% were women. The study compared a regimen including Emend and a standard regimen.
“With this expanded indication, Emend can now be used in the wider population of patients receiving moderately emetogenic chemotherapy to help prevent these worrisome and challenging side effects before they occur,” said Dr Kelly Pendergrass, clinical investigator and medical oncologist at the Kansas City Cancer Center.